問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

葉士芃

List

213Cases

2022-10-01 - 2030-05-31

Phase III

Active
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Epcoritamab

Participate Sites
5Sites

Recruiting5Sites

2025-04-01 - 2029-11-30

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2016-12-13 - 2022-05-05

Phase III

Completed
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)

  • Condition/Disease

    Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

  • Test Drug

    Venetoclax (ABT-199, GDC-0199)

Participate Sites
4Sites

Terminated3Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2013-10-01 - 2015-09-30

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2023-02-01 - 2027-12-31

Phase II

Active
Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Relapsed or Refractory Peripheral T-cell Lymphoma

  • Test Drug

    Kepida

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2017-12-19 - 2025-07-15

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-08-01 - 2024-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2022-09-30 - 2027-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-11-15 - 2025-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-12-01 - 2017-10-01

Phase III

Completed
A phase III, randomised, observer-blind, placebo- controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ herpes zoster gE/AS01B candidate vaccine when administered intramuscularly on a two- dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients.

  • Condition/Disease

    herpes zoster

  • Test Drug

    gE/AS01B vaccine

Participate Sites
5Sites

Terminated5Sites

1 4 5 6 7 8 22
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB